| To view the 2019 SABCS Abstracts, please click here. |
| 2019 SABCS Financial Disclosures |
Monday, 12/9/19
|
| 12:00 pm - 5:00 pm |
REGISTRATION - Main Lobby |
Tuesday, 12/10/19
|
| 8:00 am - 7:00 pm |
REGISTRATION - Main Lobby |
| |
|
| 11:45 am - 1:45 pm |
WORKSHOPS |
|
Molecular Biology in Breast Oncology - Hemisfair Ballroom - 3rd Level
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
Antibody-drug conjugates in cancer: Principles for synthesis and preclinical development
Gail Lewis Phillips
Genentech, Inc.
South San Francisco, CA
Defining a cancer dependency map
William C. Hahn, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
Approaches to targeting the anti-apoptotic machinery in breast cancer
Geoffrey Lindeman, MB BS, FRACP, PhD
The Walter & Eliza Hall Institute of Medical Research
Parkville, AUSTRALIA
Novel target discovery by longitudinal deep spatial & molecular analysis of breast cancers
Joe Gray, PhD
Oregon Health & Science University
Portland, OR
|
|
|
|
Developing Novel Therapeutics in the Metastatic Setting - Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Window versus neoadjuvant trial - choose wisely
Alastair M. Thompson, BSc (Hons), MB ChB, MD, FRCSEd
Baylor College of Medicine
Houston, TX
Therapeutic development in the era of precision medicine: Paradigm shift from maximum tolerated dose (MTD) to optimal biological dose (OBD)
Aditya Bardia, MD, MPH
Massachusetts General Hospital
Harvard Medical School
Boston, MA
Design and analysis of window and neoadjuvant trials
Meredith Regan, ScD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
How to talk to patients about participating in clinical trials
Patricia Spears, BSc
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC
|
| |
|
| 1:45 pm - 2:00 pm |
BREAK |
| |
|
| 2:00 pm - 7:00 pm |
EDUCATIONAL SESSIONS - Stars at Night Ballrooms 1&2, 3, 4 and Hemisfair Ballroom - 3rd Level
Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. These presentations should also provide researchers with ideas and techniques to be considered for their own studies.
|
|
| 2:00 pm - 3:30 pm |
Immunotherapy for Triple-Negative Breast Cancer – Stars at Night Ballroom 3 - 3rd Level
Moderator: Sylvia Adams, MD
NYU Langone Health
New York, NY
The emerging role of immunotherapy for the treatment of early and advanced breast cancer
Rita Nanda, MD
University of Chicago
Chicago, IL
Detecting and managing immunotherapy-related toxicities wisely
Peter Schmid, MD, PhD
Barts Cancer Institute
London, UNITED KINGDOM
Assessment of PD-L1 in breast cancer to predict response to immunotherapy
David L. Rimm, MD, PhD
Yale University School of Medicine
New Haven, CT
Evolving Opportunities to Personalize Radiation Decisions - Stars at Night Ballroom 4 - 3rd Level
Moderator: Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI
Guiding decisions to omit radiotherapy after breast-conserving surgery for DCIS. Can genomic biomarkers help?
Eileen Rakovitch, MD, MSc, FRCPC
Sunnybrook Health Sciences Centre
Toronto, CANADA
Evolving opportunities to personalize radiation decisions - Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer
Corey Speers, MD, PhD
University of Michigan
Ann Arbor, MI
Guiding selection of RT approach after lumpectomy
Simona Shaitelman, MD
University of Texas MD Anderson Cancer Center
Houston, TX
Breast Cancer Prevention – Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Targeted approach to breast cancer surveillance in high risk women: Update of the newest technologies and how to use them
Maxine S. Jochelson, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Management of high risk women: considering the time-frame
Seema A. Khan, MD
Northwestern University
Chicago, IL
Low dose tamoxifen and other approaches to improve chemoprevention uptake
Andrea De Censi, MD
E.O. Ospedali Galliera
Genova, ITALY
Acquired Endocrine Therapy Resistance Beyond ESR1 Mutations ‐ Hemisfair Ballroom - 3rd Level
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
Adaptive resistance to hormonal therapy
Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX
Single cell transcriptomcs reveals multi-step adaptation to endocrine therapy
Luca Magnani, PhD
Imperial College London
London, UNITED KINGDOM
The genomic landscape of endocrine-resistant metastatic breast cancer
Pedram Razavi, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
|
|
|
3:45 pm - 5:15 pm
|
Multidisciplinary Approaches to Optimizing Surgical Therapy for Hormone Receptor Positive Breast Cancer – Stars at Night Ballroom 3 - 3rd Level
Moderator: Armando Giuliano, MD
Cedars-Sinai Medical Center
Los Angeles, CA
Neoadjuvant therapy for hormone receptor positive breast cancer: Advances and challenges
Otto Metzger, MD
Dana-Farber Cancer Institute
Boston, MA
Regional management of the axilla prior to systemic therapy
Melissa L. Pilewskie, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Surgical considerations AFTER preoperative therapy for hormone receptor positive breast cancer
Tari Ann King, MD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA
Implementation of Genetic Testing in Breast Cancer Patients – Stars at Night Ballroom 4 - 3rd Level
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Who should have germline testing for hereditary breast cancer?
Nadine Tung, MD
Beth Israel Deaconess Medical Center
Boston, MA
Alternative practical models for genetic services in the era of increased demand
Banu Arun, MD
University of Texas MD Anderson Cancer Center
Houston, TX
Breast cancer genetic testing: moving from cancer risk assessment to therapeutic biomarker
Judith Balmaña, MD, PhD
Vall d'Hebron University Hospital
Barcelona, SPAIN
Conversations on Tough Topics Surrounding Cancer Care – Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Susan Rafte
Community Advocate, Baylor College of Medicine Breast Center
Houston, TX
Progression of disease and end of life: How to break bad news
Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
The toll on healthcare providers
Sharon H. Giordano, MD, MPH, FASCO
University of Texas MD Anderson Cancer Center
Houston, TX
The financial costs and burden of breast cancer care
Rachel A. Greenup, MD, MPH
Duke Cancer Institute
Durham, NC
Panel Discussion
Thelma P. Brown
University of Alabama at Birmingham
Birmingham, AL
Katherine O'Brien
Metastatic Breast Cancer Network
New York, NY
Endocrine Therapy in 2020 - Hemisfair Ballroom - 3rd Level
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
Adjuvant endocrine therapy in 2020: It's complicated
Ruth O'Regan, MD
University of Wisconsin Madison
Madison, WI
Future directions in endocrine therapy for advanced HR+/HER2- breast cancer
Erica L. Mayer, MD, MPH
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Everything comes at a price - Toxicity, cost and adherence to endocrine therapy
Dawn Hershman, MD
Columbia University Medical Center
New York Presbyterian Hospital
New York, NY
|
|
|
5:30 pm - 7:00 pm
|
Discussing Risk in the Context of GEP Testing - Stars at Night Ballroom 3 - 3rd Level
Moderator: Lesley Fallowfield, BSc, DPhil
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM
Discussing risk & uncertainty with patients in the context of GEP testing
Lesley Fallowfield, BSc, DPhil
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM
Communicating risk information, talking by numbers
Valerie Ann Jenkins, DPhil, BSc
Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Brighton & Sussex Medical School
Brighton, UNITED KINGDOM
Breast Cell Fate Control and Plasticity – Stars at Night Ballroom 4 - 3rd Level
Moderator: Yi Li, PhD
Baylor College of Medicine
Houston, TX
Cellular plasticity, fate, potential and lineage commitment of mammary gland stem cells
Cedric Blanpain, MD, PhD
Universite Libre de Bruxelles
Bruxelles, BELGIUM
Understanding breast cancer using a developmental perspective
Geoffrey Wahl, PhD
Salk Institute for Biological Studies
La Jolla, CA
Cell fate plasticity during breast cancer development - where is the translational utility?
Christina Scheel, MD
Helmholtz Center Munich
Institute of Stem Cell Research
Neuherberg, GERMANY
Tailoring Adjuvant Therapies Based on Neoadjuvant Response - Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Charles E. Geyer, MD
Virginia Commonwealth University
Massey Cancer Center
Richmond, VA
The biology and plasticity of residual disease after neoadjuvant treatment
Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC
Neoadjuvant systemic treatment (NST): Tailoring response by subtype
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX
Local treatment in patients who achieve pathologic complete response
Julia White, MD
The Ohio State University
Columbus, OH
Targeted Treatment Beyond PARP1 Inhibition - Hemisfair Ballroom - 3rd Level
Moderator: Alexander Bishop, DPhil
Greehey Children's Cancer Research Institute
UT Health San Antonio
San Antonio, TX
Clinical indications of PARP1 inhibitors and other targets
Melinda L. Telli, MD
Stanford University Medical Center
Stanford, CA
Targeted DNA repair in cancer and new NUDT5 inhibitors to block hormone signalling to target breast cancer
Thomas Helleday, PhD
University of Sheffield
Sheffield, UNITED KINGDOM
Clinically relevant biomarkers of PARP1 inhibitor resistance and indicators of targeted combinatorial treatments
Violeta Serra, PhD
Vall d'Hebron Institute of Oncology
Barcelona, SPAIN
|
| |
|
| 7:30 pm - 10:00 pm |
OPEN SATELLITE EVENT presented by PVI, Peer View Institute for Medical Education - Marriott Rivercenter |
|
On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
For further information and to register for this event, visit :
PeerView.com/TNBC19
|
Wednesday, 12/11/19
|
| 7:00 am - 5:15 pm |
REGISTRATION - Main Lobby
|
| |
|
| 7:00 am - 8:00 am |
CONTINENTAL BREAKFAST - Hall 2 |
| |
|
| 8:00 am - 8:15 am |
WELCOME AND OPENING REMARKS - Hall 3
Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
|
| |
|
| 8:15 am - 8:45 am |
PLENARY LECTURE 1 - Hall 3 |
|
Stromal Cells and Matrix Remodeling as Essential Regulators of the Tumor Microenvironment
Ellen Puré, PhD
University of Pennsylvania
Philadelphia, PA
|
| 8:45 am - 11:15 am |
GENERAL SESSION 1 - Hall 3
|
| |
|
| 10:45 am - 5:00 pm |
EXHIBITS - Exhibit Hall 2 |
| |
|
| 11:15 am - 12:00 pm |
WILLIAM L. MCGUIRE MEMORIAL LECTURE – Hall 3
|
| |
What would Bill think?
Joseph Sparano, MD
Montefiore Medical Center
Bronx, NY |
| |
|
| 12:00 pm - 1:00 pm |
BREAK
|
| |
|
| 12:00 pm - 1:00 pm |
CAREER DEVELOPMENT FORUM, sponsored by Eisai, Inc. - Room 304 |
| |
|
| 1:00 pm - 2:00 pm |
CLINICAL SCIENCE FORUM - Stars at Night Ballroom 3&4 - 3rd Level |
|
Frontiers in HER2 Positive Breast Cancer
Moderator: Sibylle Loibl, MD
German Breast Group
Frankfurt, GERMANY
Origins and clinical implications of HER2 heterogeneity
Andrea L. Richardson, MD, PhD
Johns Hopkins Medicine
Baltimore, MD
Emerging therapies for HER2 positive breast cancer
Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Systemic therapy for breast cancer brain metastases
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
|
| 1:00 pm - 2:00 pm |
BASIC SCIENCE FORUM 1 - Stars at Night Ballroom 1&2 - 3rd Level |
|
RNA Rewiring in Breast Cancer Progression
Moderator: Chonghui Cheng, MD, PhD
Baylor College of Medicine
Houston, TX
RNA methylation in human cancer
Chuan He, PhD
University of Chicago
Chicago, IL
Genome regulation by long noncoding RNA
Howard Chang, MD, PhD
Stanford University
Stanford, CA
|
| |
|
| 2:15 pm - 3:15 pm |
SUSAN G. KOMEN® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES - Hall 3 |
| |
SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE
|
| |
Deciphering Stem and Progenitor Cells to Understand Breast Cancer
Jane Visvader, PhD and Geoffrey Lindeman, MBBS, FRACP, PhD
The Walter and Eliza Hall Institute (WEHI)
Melbourne, AUSTRALIA |
| |
SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH
|
| |
The Molecular Etiology of Luminal-Type Breast Cancer
Matthew J. Ellis, MB BChir, BSc, PhD, FRCP
Baylor College of Medicine
Houston, TX |
| |
|
| 3:15 pm - 5:00 pm |
GENERAL SESSION 2 - Hall 3
|
| |
|
| 5:00 pm - 7:00 pm |
Spotlight Session 1: Immunotherapy in Breast Cancer: New Directions - Hemisfair Ballroom 1 - 3rd Level |
| |
|
| 5:00 pm - 7:00 pm |
Spotlight Session 2: CDK4/6 Inhibitors Resistance and Biomarkers - Stars at Night Ballroom 1&2 - 3rd Level |
| |
|
| 5:00 pm - 7:00 pm |
Spotlight Session 3: Risk/Prevention - Stars at Night Ballroom 3&4 - 3rd Level |
| |
|
| 5:00 pm - 7:00 pm |
POSTER SESSION 1 & Reception - Hall 1
|
| |
|
| 7:30 pm - 9:30 pm |
OPEN SATELLITE EVENT hosted by Research to Practice - Marriott Rivercenter
|
| |
Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer
For further information and to register for this event, visit:
http://www.researchtopractice.com/Meetings/SA2019
|
| |
|
| 7:30 pm - 10:00 pm |
OPEN SATELLITE EVENT hosted by Clinical Care Options - Marriott Riverenter |
| |
Leveraging Evolving Data Sets to Inform Treatment Decision-Making in HR-Positive, HER2-Negative Advanced Breast Cancer |
Thursday, 12/12/19
|
| 6:45 am - 5:15 pm |
REGISTRATION - Main Lobby
|
| |
|
| 7:00 am - 9:00 am |
Spotlight Session 4: Targeting HER2 and DNA Repair - Stars at Night Ballroom 1&2 - 3rd Level |
| |
|
| 7:00 am - 9:00 am |
Spotlight Session 5:
Immunooncology
Biomarkers and the Immune Landscape of Breast Cancer
- Stars at Night Ballroom 3&4 - 3rd Level |
| |
|
| 7:00 am - 9:00 am |
POSTER SESSION 2 & continental breakfast - Hall 1
|
| |
|
| 9:00 am - 9:30 am |
PLENARY LECTURE 2 - Hall 3 |
|
The Role of Radiotherapy Combined With Immunotherapy in Oligometastatic Cancer
Ralph R. Weichselbaum, MD
University of Chicago
Chicago, IL
|
| |
|
| 9:30 am - 11:30 am |
GENERAL SESSION 3 - Hall 3
|
| |
|
| 10:45 am - 5:00 pm |
Exhibits - Hall 2 |
| |
|
| 11:30 am - 12:00 pm |
AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH - Hall 3
|
| |
Essential Genes and Cistromes in
Breast Cancer
Myles Brown, MD
Dana-Farber Cancer Institute
Boston, MA |
| |
|
| 12:00 pm - 1:00 pm |
BREAK |
| |
|
| 12:00 pm - 1:00 pm |
CAREER DEVELOPMENT FORUM - Room 304 |
| |
|
| 1:00 pm - 2:00 pm |
CASE DISCUSSION 1 - Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
|
| |
|
| 1:00 pm - 2:00 pm |
TRANSLATIONAL SCIENCE FORUM 1 - Stars at Night Ballroom 3&4 - 3rd Level
|
| |
Proteogenomics of Breast Cancer, from Discovery to Precision Medicine
Moderator: Matthew J. Ellis, MD, BChir, BSc, PhD, FRCP
Baylor College of Medicine
Lester & Sue Smith Breast Center
Houston, TX
Advanced enabling technologies for cancer proteomics
Tao Liu, PhD
Pacific Northwest National Laboratory
Richland, WA
Proteogenomic landscape of prospectively collected breast cancer
Michael Gillette, MD, PhD
Broad Institute
Cambridge, MA
Proteogenomics and clinical translation
Matthew J. Ellis, MB, BChir, BSc, PhD, FRCP
Baylor College of Medicine
Houston, TX
|
| |
|
| 2:15 PM - 3:15 pm |
MINI-SYMPOSIUM 1 - Hall 3 |
| |
Future of Immuno-oncology in Breast Cancer
Moderators: Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX
and
Helen Heslop, MBChB, MD, DSc
Baylor College of Medicine
Houston, TX
Immunotherapy in breast cancer: enhancing response to checkpoint blockade
Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA
T cell-based immunotherapy for a "public" neoantigen derived from a PIK3CA hotspot mutation
Christopher A. Klebanoff, MD
Memorial Sloan Kettering Cancer Center
New York, NY
|
| |
|
| 3:15 pm - 5:00 pm |
GENERAL SESSION 4 - Hall 3
|
| |
|
| 5:00 pm - 7:00 pm |
Spotlight Session 6: Local Regional Therapy/DCIS - Hemisfair Ballroom 1 - 3rd Level |
| |
|
| 5:00 pm - 7:00 pm |
Spotlight Session 7: The Science of ER Resistance and Emerging Clinical Strategies - Stars at Night Ballroom 1&2 - 3rd Level |
| |
|
| 5:00 pm - 7:00 pm |
Spotlight Session 8: The Metastatic Landscape - Drug Resistance and Metastasis Biology - Stars at Night Ballroom 3&4 - 3rd Level |
| |
|
| 5:00 pm - 7:00 pm |
POSTER SESSION 3 & Reception - Hall 1
|
| |
|
7:30 pm
|
OPEN SATELLITE EVENT presented by Harborside Medical Education - Marriott Rivercenter
|
| |
Breast Cancer Brain Metastases: Key Strategies for Optimal Management
For further information and to register for this event, visit
https://www.eventbrite.com/e/breast-cancer-brain-metastases-key-strategies-for-optimal-management-registration-71692294583
|
| |
|
| 7:30 pm |
OPEN SATELLITE EVENT presented by Research to Practice - Marriott Rivercenter
|
| |
Data + Perspectives: Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer
For further information and to register for this event, visit
http://www.researchtopractice.com/Meetings/SA2019
|
Friday, 12/13/19
|
| 6:45 am - 5:15 pm |
REGISTRATION - Main Lobby
|
| |
|
| 7:00 am - 9:00 am |
Spotlight Session 9: Detection and Treatment Response Assessment - Stars at Night Ballroom 1&2 - 3rd Level
|
| |
|
| 7:00 am - 9:00 am |
Spotlight Session 10: Toxicity, Tolerability & Cost - Stars at Night Ballroom 3&4 - 3rd Level |
| |
|
| 7:00 am - 9:00 am |
POSTER SESSION 4 & continental breakfast - Hall 1
|
| |
|
| 9:00 am - 9:45 am |
DEBATE - Hall 3
|
| |
Mastectomy should not be offered to patients who are breast conservation candidates when modern radiotherapy is available
Chairman: Richard Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX
Lawrence B. Marks, MD, FASTRO
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC
Alastair M. Thompson, ALCM, BSc(Hons) MBChB, MD, FRCSEd(Gen)
Baylor College of Medicine
Houston, TX
|
| |
|
| 9:45 am - 11:30 am |
GENERAL SESSION 5 - Hall 3
|
| |
|
| 10:45 am - 5:00 pm |
EXHIBITS - Hall 2 |
| |
|
| 11:30 am- 12:00 pm |
2019 AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH, SUPPORTED BY THE BREAST CANCER RESEARCH FOUNDATION - Hall 3
|
| |
Novel Non-canonical Functions of EZH2 in Triple Negative Breast Cancer
Celina Kleer, MD
University of Michigan Medical School
Ann Arbor, MI
|
| |
|
| 12:00 pm - 1:00 pm |
BREAK
|
| |
|
| 12:00 pm - 1:00 pm |
NETWORKING WITH THE EXPERTS - Hall 2 |
| |
|
| 1:00 pm- 2:00 pm |
CASE DISCUSSION 2 - Stars at Night Ballroom 1&2 - 3rd Level
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
|
| |
|
| 1:00 pm - 2:00 pm |
TRANSLATIONAL SCIENCE FORUM 2 – Stars at Night Ballroom 3&4 - 3rd Level
|
| |
The Communal Road to Metastasis: CTC Clusters
Moderator: Rachel Schiff, PhD
Baylor College of Medicine
Lester & Sue Smith Breast Center
Houston, TX
CTC clusters, cancer stemness, and new treatment strategies
Huiping Liu, MD, PhD
Northwestern University
Chicago, IL
Biology, vulnerabilities and clinical implications of CTC clusters
Nicola Aceto, PhD
University of Basel
Basel, SWITZERLAND
|
| |
|
| 2:15 pm - 3:15 pm |
MINI-SYMPOSIUM 2 - Hall 3
|
| |
Targeting the Cell Cycle Kinase CDK 4/6 and Beyond
Moderator: Angela DeMichele, MD, MSCE
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Mechanisms of resistance to CDK4/6 inhibitors and new therapeutic approaches
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Targeting the cell cycle - Beyond CDK4/6 inhibition
Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA
|
| |
|
| 3:15 pm - 5:00 pm |
GENERAL SESSION 6 - Hall 3
|
| |
|
| 5:00 pm - 7:00 pm |
POSTER SESSION 5 & Reception - Hall 1
|
| |
|
| 6:00 pm - 7:30 pm |
SPECIAL SESSION - Stars at Night Ballroom 3&4 - 3rd Level
|
| |
View from the Trenches: What Will You Do On Monday Morning?
Moderator: Ruth O'Regan, MD
University of Wisconsin
Carbone Cancer Center
Madison, WI
Panel Members:
Nadia Harbeck, MD, PhD
Ludwig Maximilian University of Munich
Munich, GERMANY
E. Shelley Hwang, MD, MPH
Duke University
Durham, NC
Debra A. Patt, MD, MPH
Texas Oncology
Austin, TX
Bárbara Segarra-Vázquez, DHSc
University of Puerto Rico
San Juan, PR
Joseph Sparano, MD
Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, NY |
| |
|
| 7:30 pm |
OPEN SATELLITE EVENT presented by Research to Practice - Marriott Rivercenter
Data + Perspectives: Clinical Investigators Explore the Current and Future Management of HER2- Positive Breast Cancer
For further information and to register for this event, visit
http://www.researchtopractice.com/Meetings/SA2019
|
| |
|
Saturday, 12/14/19
|
| |
| 6:45 am - 9:00 am |
Registration - Main Lobby
|
| |
|
| 7:00 am - 9:00 am |
POSTER SESSION 6 & continental breakfast - Hall 1 |
| |
|
| 9:00 am - 11:00 am |
The Year in Review - Hall 3
|
| |
Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
Basic science
Alana L. Welm, PhD
University of Utah
Huntsman Cancer Institute
Salt Lake City, UT
Translational research
Geoffrey Lindeman, MBBS, FRACP, PhD
The Walter & Eliza Hall Institute of Medical Research
Parkville, AUSTRALIA
Early breast cancer
Masakazu Toi, MD, PhD
Kyoto University
Kyoto, JAPAN
Metastatic breast cancer
Sara Hurvitz, MD
University of California, Los Angeles
Los Angeles, CA
|
| |
|
| 11:00 am |
Adjournment |
| |